Hepatocyte growth factor, its receptor, and their potential value in cancer therapies

被引：219

作者：

Jiang, WG

Martin, TA

Parr, C

Davies, G

Matsumoto, K

Nakamura, T

机构：

[1] Cardiff Univ, Walles Coll Med, Dept Surg, Metastasis & Angiogenesis Res Grp, Cardiff CF14 4XN, S Glam, Wales

[2] Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, Suita, Osaka, Japan

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2005年 / 53卷 / 01期

关键词：

hepatocyte growth factor; HGF; cMET; cancer metastasis; angiogenesis; signal transduction; cancer therapies;

D O I：

10.1016/j.critrevonc.2004.09.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocyte growth factor plays multiple roles in cancer, by acting as a motility and invasion stimulating factor, promoting metastasis and tumour growth. Furthermore, it acts as a powerful angiogenic factor. The pivotal role of this factor in cancer has indicated HGF as being a potential target in cancer therapies. The past few years have seen rapid progress in developing tools in targeting HGF, in the context of cancer therapies, including development of antagonists, small compounds, antibodies and genetic approaches. The current article discusses the potential value of HGF and its receptor as targets in cancer therapies, the current development in anti-HGF research, and the clinical value of HGF in prognosis and treatment. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：35 / 69

页数：35

共 320 条

[1] Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells
Abiru, S
Nakao, K
Ichikawa, T
Migita, K
Shigeno, M
Sakamoto, M
Ishikawa, H
Hamasaki, K
Nakata, K
Eguchi, K
[J]. HEPATOLOGY, 2002, 35 (05) : 1117 - 1124
[2] In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis
Abounader, R
Lal, B
Luddy, C
Koe, G
Davidson, B
Rosen, EM
Laterra, J
[J]. FASEB JOURNAL, 2001, 15 (13) : 108 - +
[3] Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity
Alexandrakis, MG
Passam, FH
Sfiridaki, A
Kandidaki, E
Roussou, P
Kyriakou, DS
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2003, 72 (04) : 229 - 233
[4] Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation
Baatar, D
Jones, MK
Pai, R
Kawanaka, H
Szabo, IL
Moon, WS
Kitano, S
Tarnawski, AS
[J]. AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (03) : 963 - 972
[5] Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase
Benaud, C
Oberst, M
Hobson, JP
Spiegel, S
Dickson, RB
Lin, CY
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (12) : 10539 - 10546
[6] Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor
Benaud, C
Dickson, RB
Lin, CY
[J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (05): : 1439 - 1447
[7] Deregulated activation of matriptase in breast cancer cells
Benaud, CM
Oberst, M
Dickson, RB
Lin, CY
[J]. CLINICAL & EXPERIMENTAL METASTASIS, 2002, 19 (07) : 639 - 649
[8] Beppu K, 2000, ANTICANCER RES, V20, P1263
[9] CAN HAMMERHEAD RIBOZYMES BE EFFICIENT TOOLS TO INACTIVATE GENE-FUNCTION
BERTRAND, E
PICTET, R
GRANGE, T
[J]. NUCLEIC ACIDS RESEARCH, 1994, 22 (03) : 293 - 300
[10] Met, metastasis, motility and more
Birchmeier, C
Birchmeier, W
Gherardi, E
Vande Woude, GF
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) : 915 - 925

← 1 2 3 4 5 6 7 8 9 10 →